Home/Filings/4/0001181431-07-067126
4//SEC Filing

HEMOSENSE INC 4

Accession 0001181431-07-067126

CIK 0001127393operating

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 1:11 PM ET

Size

18.0 KB

Accession

0001181431-07-067126

Insider Transaction Report

Form 4
Period: 2007-11-06
Merselis James D
DirectorPresident, CEO10% Owner
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-06145,0000 total
    Exercise: $0.80Exp: 2012-06-05Common Stock (145,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-0628,3700 total
    Exercise: $8.60Exp: 2017-05-24Common Stock (28,370 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-06113,7500 total
    Exercise: $0.80Exp: 2015-02-17Common Stock (113,750 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-0646,6300 total
    Exercise: $8.60Exp: 2017-05-24Common Stock (46,630 underlying)
  • Disposition to Issuer

    Common Stock

    2007-11-0650,0000 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-0624,1250 total
    Exercise: $0.80Exp: 2013-07-11Common Stock (24,125 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2007-11-0640,0000 total
    Exercise: $6.23Exp: 2016-02-06Common Stock (40,000 underlying)
Footnotes (2)
  • [F1]Disposed of pursuant to merger agreement between issuer and Inverness Medical Innovations, Inc. ("Inverness") in exchange for shares of Inverness common stock on the effective date of the merger, November 6, 2007. The number of shares of common stock issued by Inverness is equal to the number of shares of HemoSense common stock held multiplied by the exchange ratio of 0.274192, with the resulting aggregated share number rounded down to the next whole share and fractional shares paid in cash.
  • [F2]This option was assumed by Inverness in the merger and replaced with an option to purchase shares of Inverness common stock. The number of shares of Inverness common stock subject to the assumed option is calculated by multiplying the number of shares of HemoSense common stock subject to the options held by 0.274192, rounded down on a per-option basis to the next whole share. The exercise price of the assumed option is equal to the exercise price of the HemoSense option divided by 0.274192, rounded up to the next cent.

Issuer

HEMOSENSE INC

CIK 0001127393

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001127393

Filing Metadata

Form type
4
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 1:11 PM ET
Size
18.0 KB